AnteoTech Outlines Dual Market Growth Strategy at Gold Coast Showcase
AnteoTech outlines dual-market growth strategy at Gold Coast showcase
In its June 2026 investor presentation, AnteoTech outlined its position as an advanced chemical and materials company operating two commercial businesses that address combined markets exceeding US$60 billion annually. The Brisbane-based firm specialises in surface modification technology, delivering molecular-level cross-linking solutions across Life Sciences diagnostics and Advanced Battery Technologies.
Management detailed a pro-forma cash position of $12.8 million as at 31 March 2026, bolstered by $9.5 million from option exercises completed 29 May 2026 (net of fees). The company carries no debt and is generating revenues. AnteoTech’s market capitalisation stood at $88 million as at 9 June 2026.
The presentation highlighted multiple near-term commercial catalysts, including independent third-party validation of the company’s Ultranode™ 95 anode technology for drone applications, ongoing Joint Development Agreement (JDA) negotiations with US battery manufacturers, and market expansion into Chemiluminescence (CLIA) diagnostics through strategic partnerships.
When big ASX news breaks, our subscribers know first
What is surface modification technology?
AnteoTech’s core technology centres on molecular-level cross-linking — a process that binds molecules together and attaches molecules to surfaces. In simplified terms, the company’s chemistry acts as a performance-enhancing adhesive that improves how materials stick together and function.
This underlying science is protected through 17 patents and applies across diverse applications. The same cross-linking principles that improve battery anode performance also enhance diagnostic assay sensitivity. Management positioned the company as a platform technology business rather than a single-product entity.
Potential applications extend beyond batteries and diagnostics to include superconductors, PFAS water treatment, industrial coatings, filtration systems, and synthetic textiles. The presentation emphasised that this breadth of application creates multiple pathways for value creation across end markets.
Advanced Battery Technologies — Ultranode and new product expansion
The presentation outlined AnteoTech’s expanded battery product portfolio, targeting distinct segments within the lithium-ion battery supply chain. The suite comprises four primary offerings: Anteo X® (a cross-linking performance additive for silicon anodes), SiMRAX (a binder strengthening system combining Anteo X with single-walled carbon nanotubes), Ultranode™ (high silicon anode formulations available in three variants), and Anteo S™ (a separator structural performance additive).
Management reported a significant validation milestone: independent, third-party confirmation of Ultranode™ 95 MLP performance for drone applications, achieved at the Battery Innovation Center in commercial cell format. This validation supports the company’s US market entry strategy for defence and unmanned aerial systems.
The Ultranode 95 commercial cell validation at the Battery Innovation Center in Indiana confirmed more than 300 cycles at 70% capacity retention in 5 Ah Multi-Layer Pouch format cells, with BIC describing the scale-up process as among the most straightforward it had observed.
The three Ultranode variants target different application segments. Ultranode X is designed for automotive and electric vertical take-off and landing (eVTOL) markets, prioritising high cycle life exceeding 1,000 cycles at 80% capacity retention. Ultranode 70 addresses consumer electronics and micro-mobility applications, with evaluation underway at Wyon. Ultranode 95 targets unmanned aerial systems, drones, and defence markets, where maximum energy density outweighs cycle life requirements. Management stated that 2 Joint Development Agreements with US battery manufacturers for drone applications are under negotiation.
The presentation cited market sizing data positioning the high silicon anode market at US$540 million in 2025, growing at a 45% compound annual growth rate (CAGR). The ceramic coated separator market was valued at US$2 billion with a 21% CAGR as at 2024.
| Ultranode Variant | Target Application | Coating Capacity | Cycle Life Target |
|---|---|---|---|
| Ultranode X | Automotive & eVTOLs | 700-1,100 mAh/g | >1,000 cycles @ 80% |
| Ultranode 70 | Consumer electronics, micro-mobility | 700-1,100 mAh/g | >500 cycles @ 80% |
| Ultranode 95 | Drones, UAS, defence | 1,800-2,400 mAh/g | >200 cycles @ 80% |
Silicon stores approximately 10 times more lithium ions by weight than graphite (3,579 mAh/g theoretical capacity versus 371 mAh/g). Management highlighted Ultranode 95’s superior energy density — with specific energy exceeding 390 Wh/kg at cell level — as a differentiator for defence and drone markets where flight time and payload capacity are critical performance metrics.
Anteo S — addressing battery safety in a US$2 billion market
The company’s Anteo S™ product functions as a cross-linker for ceramic coated separators (CCS), targeting battery safety applications. The technology improves thermal stability, reduces thermal runaway risk, and enhances puncture resistance in lithium-ion batteries.
Management announced a strategic collaboration and sales agreement with Xerabrid in South Korea on 26 May 2026. The partnership positions Anteo S within the ceramic coated separator supply chain, addressing safety concerns particularly relevant to Battery Energy Storage Systems (BESS) and electric vehicle applications.
The presentation referenced separator market projections for 2032, with automotive applications representing 51% of demand, consumer electronics 24%, and energy storage systems 13%. BESS safety incidents — including a September 2024 thermal runaway event at a California substation — underscore the commercial drivers for improved separator technology.
The ceramic coated separator market was valued at US$2 billion with a 21% CAGR as at 2024, representing a newer product opening for AnteoTech with substantial addressable market potential. Management positioned Anteo S as targeting high-volume sales opportunities where safety performance carries premium value.
Life Sciences — CLIA and ELISA market expansion
Management outlined the company’s strategic expansion into new diagnostic immunoassay segments beyond its existing lateral flow business. The global diagnostic immunoassays market generates US$56 billion in annual revenue, growing at a 9% CAGR as at 2024.
The market entry strategy centres on two platforms. For Chemiluminescence (CLIA), AnteoTech published a White Paper in March 2026 demonstrating that AnteoBind NXT™ outperformed incumbent market products across three key metrics: up to 1.8 times higher signal-to-blank ratio (improved sensitivity), up to 6 times lower antibody usage (cost reduction), and activation time reduced from 20 hours to 2 hours (workflow improvement). A collaboration with a large life sciences company is progressing CLIA development.
The CLIA development partnership with the large life sciences company was announced in March 2026, requiring technical milestones to be achieved before progressing to a joint product development agreement, with AnteoBind NXT’s antibody efficiency gains potentially cutting capture antibody costs by a material margin.
For Enzyme-Linked Immunosorbent Assay (ELISA) applications, a prototype product is undergoing testing at the Serum Institute of India (SII), with whom AnteoTech holds a 5-year contract valued at US$1.8 million.
The company’s distribution network has expanded through two recent appointments: Cosmo Bio as Japanese distributor (May 2026) and local Indian business development resources engaged in mid-April 2026. The existing SII contract anchors the Indian market presence.
Management cited the CLIA market at an estimated US$13 billion annually as at 2024, with consumables representing 66% of the market. Antibodies plus CLIA particles constitute 50% to 90% of total consumables expenditure.
The presentation detailed a value-chain strategy for CLIA market entry. AnteoTech is assessing supply of activation kits containing magnetic particles (sourced through its global supply network), AnteoBind NXT activation reagents, and optimised protocols. Kits would be packaged within target markets to meet local regulatory and customer requirements. This approach positions the company to capture higher-margin consumables revenue rather than reagent-only sales.
Global market development and near-term catalysts
Management mapped geographic expansion across five key regions. In the United States, Battery Innovation Center validation has been achieved, two drone JDAs are under negotiation, and the company plans to attend the Association for Diagnostics & Laboratory Medicine (ADLM) conference in late July 2026 for new product launch activities. South Korea partnerships include the Xerabrid collaboration for Anteo S and an existing Kangshin ABT relationship. Japan market access has been secured through the Cosmo Bio distribution agreement. In Europe, Wyon’s evaluation of Ultranode 70 is underway alongside a CLIA collaboration with a large life sciences company. India development centres on the SII contract and local business development resource scaling.
The sample evaluation pipeline stood at 19 Advanced Battery Technologies samples and 14 Life Sciences samples under evaluation as at 11 June 2026.
Management outlined four near-term priority targets:
- Drone anode Joint Development Agreements secured in the US
- CLIA strategic partnerships and/or pilot market entry
- Anteo S sales and strategic collaboration progression
- R&D tax rebate claim expedited
The presentation positioned US defence drone market entry and CLIA strategic partnerships as priority focus areas over the next 12 months, with multiple potential catalysts across both business divisions.
The next major ASX story will hit our subscribers first
Capital structure and board overview
The company’s capital structure as at 9 June 2026 comprised 3,259.8 million shares on issue and 292 million unlisted options. Of the options outstanding, 30% expire in 2026 and 52% in 2028, with employee and director options representing 26% of the total. The top 20 shareholders hold 23% of issued capital.
The board composition comprises three directors. Glenda McLoughlin serves as Non-Executive Chair, bringing investment banking experience from Morgan Stanley, Credit Suisse, and Barclays, with sector expertise in energy and infrastructure. Dr. Geoff Cumming holds a Non-Executive Director role, with a career spanning research, sales, marketing, and executive positions at Roche. He also serves on the board of INOVIQ Ltd (ASX:IIQ). Merrill Gray was appointed Managing Director and CEO on 19 August 2025, following interim appointments as Non-Executive Director (30 January 2025) and Interim Managing Director (18 April 2025). Gray’s background spans battery technology (including cathode active materials, graphite, and recycling), hydrogen, and renewable energy sectors.
The $9.5 million option exercise completed 29 May 2026 strengthened the pro-forma cash position to $12.8 million, providing capital for commercial execution across both divisions without debt obligations.
Want the Next Battery Tech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to get Advanced Materials and Battery Technology alerts delivered straight to your inbox the moment market-moving announcements hit the ASX.